AB Science will host a live webcast on Monday December 16, 2024, from 5.30pm to 6.30pm CET PRESS RELEASE…
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS PRESS RELEASE…
AB Science announces positive results of its Phase 2 study evaluating masitinib in Covid-19 PRESS RELEASE…
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS PRESS RELEASE…
AB Science reports its revenues for the year 2023 and provides an update on its activities PRESS RELEASE…
AB Science : The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science PRESS RELEASE…
AB Science announces a slight delay in the publication of its 2023 annual financial report PRESS RELEASE…
AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS PRESS RELEASE…
AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development PRESS RELEASE…
AB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the Company PRESS RELEASE…
AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET PRESS RELEASE…
AB Science announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) for masitinib in ALS PRESS RELEASE…